Pure Global
NCT01760421

The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis

National Taiwan University Hospital·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hashimoto Thyroiditis
Drug/Device/Intervention
Hydroxychloroquine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Taiwan University Hospital
Location
Taipei, Taiwan
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2011
End date
Aug 01, 2013
Enrollment
40 participants
Primary outcome

Anti-TPO antibody,Anti-thyroglobulin antibody

Summary

Hashimoto's thyroiditis is an autoimmune thyroid disease, which induced chronic inflammation
 of thyroid gland and destroys thyroid tissue.
 
 Hydroxychloroquine is used as disease modifying anti-rheumatic drug (DMARD) for treatment of
 several autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid
 arthritis(RA) for more than one century.
 
 The purpose of this study is to evaluate whether hydroxychloroquine is effective in treatment
 of Hashimoto's thyroiditis.

ICD-10 classifications
ThyroiditisThyroiditis, unspecifiedDisorders of thyroid glandDisorder of thyroid, unspecifiedOther disorders of thyroid
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01760421
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01760421 through Pure Global AI's free database. This phase not specified trial is sponsored by National Taiwan University Hospital and is currently Completed. The study focuses on Hashimoto Thyroiditis. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.